Histiocytosis, Langerhans-Cell
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- Blood1
Leading researchers8
- Abdo A1
- Cao XX1
- Cohen-Aubart F1
- Collin M1
- Dagna L1
- Diamond EL1
- Durham BH1
- Estrada-Veras JI1
Affiliations (unnormalised)6
- Ariel University1
- Baylor College of Medicine1
- Cincinnati Children's Hospital Medical Center1
- Clinic of Histiocytic Neoplasms1
- Columbia University Medical Center1
- Dana-Farber Cancer Institute1
Reference
Authoritative identity, definition & identifiers.
A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.